In vitro and in vivo evaluations of LB10517, a novel parentral broad-spectrum cephalosporin

Archives of Pharmacal Research

Volumn 19, Issue 1, 1996, Pages 46-51

  Song, Hye Kyong ^a   Nishino, Takeshi ^b   Seo, Mi Kyeong ^a   Kim, Mu Yong ^a   Lee, Yong Hee ^a   Kim, In Chull ^a   Kwak, Jin Hwan ^a  

^a LG Chemical Ltd   (South Korea)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Catechol; Cephalosporin; LB10517; MIC; tonB

Indexed keywords

CEFLUPRENAM; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; IMIPENEM; LB 10517; OFLOXACIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOKINETICS; RAT;

EID: 0030438199     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02976819     Document Type: Article

References (15)

1. Aisen, P., Iron transport and storage proteins. Ann. Rev. Biochem. 49, 357-393 (1980).
2. Arisawa, M., Sekine, Y., Shimizu, S., Takano, H., Angehrn, P. and Then, R. L., In vitro and in vivo evaluation of Ro 09-1428, a new parenteral cephalosporin with high antipseudomonal activity. Antimicrobial Agents and Chemotherapy, 35, 653-659 (1991).
3. Bennett, J. V., Brodie, J. L., Benner, E. J., and Kirby, W. M., Simplified and accurate method for antibiotic assay of clinical specimens. Applied Microbiology, 14, 170-177 (1966).
4. Barclay, R., The role of iron in infection. Med. Lab. Sci., 42, 166-177 (1985).
5. Committee for Revision of MIC Determination Method, Revision of minimal inhibitory concentration (MIC) determination method. Chemotherapy (Tokyo), 29, 76-79 (1981).
6. Curtis, N. A. C., Eisenatadt, R. L., East, S. J., Cornford, R. J., Walker, L. A. and White, A. J., Iron-regulated outer membrane proteins of E. coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimocrobial Agents and Chemotherapy, 32, 1879-1886 (1988).
7. Erwin, M. E., Jones, R. N., Barrett, B. M. and Johnson, D. M., In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin. Antimicrobial Agents and Chemotherapy, 35 (5), 929-937 (1991).
8. Hartmann, A and Braun, V., Iron transport in E coli: Uptake and modification of ferrichrome. J. Bacteriol., 143, 246-255 (1980).
9. Hata, K., Otsuki, M.,and Nishino, T., In vitro and in vivo antibacterial activities of E-1077, a novel parenteral cephalosporin with a broad antibacterial spectrum, Antimicrobial Agents and Chemotherapy, 36, 1894-1901 (1992)
10. Kwak, J. H., Kim, S. I., Oh, J. I., Song, H. K., Kim, M. Y., Seo, M. K., Jeong, Y. N., Lee, Y. H., Kim, Y. Z. and Kim, I. C., In vitro and in vivo activities of LK 10517, a novel catechol-substituted cephalosporin. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract F93, p. 160. American Society for Microbiology, Washington, DC (1994).
11. Nakagawa, S., Sanada, M., Matsuda, K., Hazumi, N. and Tanaka, N., Biological activity of BO-1236, a new antipseudomonal cephalosporin. Antimicrobial Agents and Chemotherapy, 31, 1100-1105 (1987).
12. Seibert, G., Limbert, M., Winkler, I. and Dick, T., Antibacterial activity in vitro and β-lactamase stability of the new cephalosporin HR810 in comparison with five other cephalosporins and two aminoglycosides. Infection, 11, 275-279 (1983).
13. Silley, P., Griffiths, J. W., Monsey, D. and Harris A. M., Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system. Antimicrobial Agents and Chemotherapy, 34, 1806-1808 (1990).
14. Watanabe, N-A., Hiruma, R., and Katsu, K., In vitro evaluation of E-1077, a new cephalosporin with a broad antibacterial spectrum. Antimicrobial Agents and Chemotherapy, 36, 589-597 (1992)
15. Weinberg, E. D., Iron and infection. Microbiol. Rev., 42, 45-66 (1978).